The CAR-T Revolution: How Novartis & Gilead Launched Next-Gen Cancer Therapies

🔗 Download a free excerpt of our exclusive CAR-T Case Study here: https://www.best-in-class.com/rw353.htm

In this video, we explore how Novartis and Gilead revolutionized cancer treatment in 2017 with the launch of chimeric antigen receptor T-cell (CAR-T) therapies, Kymriah and Yescarta. These groundbreaking therapies re-engineer a patient’s own T-cells to target and destroy cancer cells, offering a one-time treatment with the potential for lasting remission.

Join us as we uncover the story behind these therapies, from their fast-tracked approvals to the key challenges they've faced in pricing, manufacturing, and market adoption. Learn why CAR-T therapies, despite their promising results, have struggled to gain widespread utilization and what the future holds for next-generation CAR-T treatments.

📥 Download our free report summary now: https://www.best-in-class.com/rw353.htm

📧 For more information or to address any other benchmarking needs, reach out to us at [email protected]

👍 Subscribe now for more updates on the latest advancements in oncology and cancer therapies!

#CART #CancerTreatment #PharmaLaunch #ProductLaunch #OncologyInnovation #Gilead #Novartis #CARTTherapies #CARTChallenges #HealthcareInnovation #Pharma #BestPracticesLLC